Quote this publication Share Print

OTEZLA (apremilast), PDE4 inhibitor immunosuppressant

DERMATOLOGY - New medicinal product
Opinions on drugs - Posted on Apr 15 2016

Reason for request

Inclusion

No clinical benefit demonstrated in moderate to severe chronic plaque psoriasis

  • OTEZLA (oral) has a Marketing Authorisation in the treatment of moderate to severe chronic plaque psoriasis in adult patients in case of failure, contraindication or intolerance to other systemic treatments including ciclosporin, methotrexate or PUVA therapy.
  • Its modest efficacy has been demonstrated compared with placebo in patients refractory to topical treatments. No clinical benefit has been demonstrated compared with other conventional or biological systemic treatments.
  • It is a second-line systemic treatment, after failure of other non-biological systemic treatments. It can be useful for delaying the start of treatment with biotherapy.




Clinical Benefit

Moderate

-

Low
Insufficient

Clinical Added Value

no clinical added value

-


Therapeutic use

-

Contact Us

Évaluation des médicaments